Noble Financial Issues Optimistic Outlook for CVKD Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Research analysts at Noble Financial increased their Q3 2025 EPS estimates for Cadrenal Therapeutics in a research note issued to investors on Tuesday, August 12th. Noble Financial analyst R. Leboyer now forecasts that the company will earn ($1.55) per share for the quarter, up from their previous estimate of ($1.56). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. Noble Financial also issued estimates for Cadrenal Therapeutics’ Q4 2025 earnings at ($1.83) EPS, FY2025 earnings at ($7.19) EPS and FY2026 earnings at ($5.42) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its earnings results on Monday, August 11th. The company reported ($1.87) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.27).

Separately, HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of Cadrenal Therapeutics in a research note on Friday, May 16th.

Cadrenal Therapeutics Price Performance

NASDAQ CVKD opened at $12.68 on Thursday. Cadrenal Therapeutics has a 12 month low of $5.70 and a 12 month high of $22.90. The company has a market capitalization of $25.99 million, a price-to-earnings ratio of -1.43 and a beta of 0.93. The company’s fifty day moving average price is $11.98 and its two-hundred day moving average price is $15.27.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cadrenal Therapeutics stock. Geode Capital Management LLC bought a new position in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,554 shares of the company’s stock, valued at approximately $153,000. Geode Capital Management LLC owned 0.59% of Cadrenal Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 7.92% of the stock is owned by institutional investors.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.